Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Intangibles (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Intangibles of $592.8 million for Q4 2025, up 117.84% on a QoQ basis from $272.1 million in Q4 2024, and up 117.84% year-over-year from $272.1 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Intangibles data on file, last reported at $592.8 million in Q4 2025.

  • In Q4 2025, Intangibles rose 117.84% year-over-year to $592.8 million; the TTM figure through Dec 2025 stood at $592.8 million (up 117.84% YoY), while the FY2025 annual figure was $592.8 million, up 129.9% from the prior year.
  • Intangibles advanced to $592.8 million in Q4 2025, from $272.1 million in the prior quarter.
  • Across five years, Intangibles topped out at $592.8 million in Q4 2025 and bottomed at $71.4 million in Q4 2023.
  • A 3-year average of $312.1 million and a median of $272.1 million in 2024 frame the typical range for Intangibles.
  • Annual changes were most pronounced in 2024 — Intangibles jumped 281.2% — and 2025, when it jumped 117.84%.
  • Year by year, Intangibles stood at $71.4 million in 2023, then jumped by 281.2% to $272.1 million in 2024, then jumped by 117.84% to $592.8 million in 2025.
  • The last three Intangibles figures came in at $592.8 million (Q4 2025), $272.1 million (Q4 2024), and $71.4 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Intangibles (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 4.41 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 11,640.44
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 30.30 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 418.50 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.29 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn - 592.82 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 592.82 Mn
Dec 31, 2024 272.13 Mn
Dec 31, 2023 71.39 Mn